Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Surrogate endpoints].

C Hill1

  • 1Institut Gustave-Roussy, 94805 Villejuif Cedex.

Bulletin Du Cancer
|September 8, 1999
PubMed
Summary
This summary is machine-generated.

Phase III oncology trials require clinically relevant endpoints like overall survival. Surrogate endpoints, while useful in Phase II trials for speed, should only be used in Phase III if their validity is proven and they accurately predict clinical outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the new national health standard for rail safety workers on ischaemic heart disease risk factors in train drivers.

Internal medicine journal·2012
Same author

Zeroing out dioxins:.

New solutions : a journal of environmental and occupational health policy : NS·2012
Same author

Production of the antimicrobial peptides Caseicin A and B by Bacillus isolates growing on sodium caseinate.

Letters in applied microbiology·2012
Same author

Search for signatures of extra dimensions in the diphoton mass spectrum at the large hadron collider.

Physical review letters·2012
Same author

Search for the standard model Higgs boson in the decay channel H→ZZ→4ℓ in pp collisions at √s=7 TeV.

Physical review letters·2012
Same author

New measurements of high-momentum nucleons and short-range structures in nuclei.

Physical review letters·2012
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Trials
  • Biostatistics

Context:

  • Phase III oncology trials necessitate clinically relevant endpoints, typically disease-free or overall survival.
  • These primary endpoints require extensive patient cohorts and long-term follow-up.
  • Phase II trials prioritize rapid assessment using surrogate endpoints.

Purpose:

  • To evaluate the appropriate use of surrogate endpoints in clinical trials.
  • To define criteria for the valid application of surrogate endpoints in Phase III oncology studies.
  • To emphasize the importance of clinical relevance and predictive accuracy for surrogate endpoints.

Summary:

  • Surrogate endpoints are suitable for Phase II trials due to their speed.
  • Their application in Phase III trials is limited to specific scenarios where validity is established.

Related Experiment Videos

  • A valid surrogate endpoint must be faster to measure than the clinical endpoint and fully capture treatment effects.

    • Impact:

    • This research informs the design and interpretation of oncology clinical trials.
    • It guides the judicious selection of endpoints to ensure both efficiency and clinical meaningfulness.
    • Promotes rigorous evaluation of therapeutic interventions by emphasizing validated surrogate endpoints.